M
2181
vs
H
Hang Seng (Hong Kong)
Over the past 12 months, Mabpharm Ltd has outperformed Hang Seng (Hong Kong), delivering a return of +16% compared to the Hang Seng (Hong Kong)'s +5% growth.
Stocks Performance
2181 vs Hang Seng (Hong Kong)
Performance Gap
2181 vs Hang Seng (Hong Kong)
Performance By Year
2181 vs Hang Seng (Hong Kong)
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Mabpharm Ltd
Glance View
Mabpharm Ltd. engages in the research, development, and manufacture of monoclonal antibody drugs for the treatment of cancer and autoimmune diseases. The company is headquartered in Taizhou, Jiangsu. The company went IPO on 2019-05-31. The firm's main products include omalizumab (CMAB007), cetuximab (CMAB009) and infliximab (CMAB008). The firm mainly conducts its businesses in China market.